Patents Examined by Rodney P Swartz
  • Patent number: 11224652
    Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 16 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 9V, 12F, 14, 18C, 19A, 19F, 22F, 23F, and 33F, wherein two of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM197, and wherein the two capsular polysaccharides that are conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, and 5. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: January 18, 2022
    Assignees: SANOFI PASTEUR INC., SK BIOSCIENCE CO., LTD.
    Inventors: Kyungjun An, Wooyoung Choi, Dongsoo Ham, Hun Kim, Jinhwan Shin, Robert Hopfer, Richard D. Kensinger, Moe Kyaw, Eric Desauziers, Clotilde El Guerche Seblain, Philippe Talaga
  • Patent number: 11225509
    Abstract: Provided herein are HER2-targeting molecules comprising Shiga toxin A Subunit derived polypeptides having 1) de-immunization and 2) reduced, protease-cleavage sensitivity while retaining Shiga toxin function(s), such as, e.g., potent cytotoxicity via ribosome inhibition. Certain HER2-targeting molecules of the present invention exhibit reduced immunogenic potential in mammals and are well-tolerated by mammals while retaining aforementioned features. The HER2-targeting molecules of the present invention have uses for selectively killing specific cells (e.g., HER positive tumor cells); for selectively delivering cargos to specific cells (e.g., HER positive tumor cells), and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers and tumors involving the expression or over-expression of cell-surface HER2.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: January 18, 2022
    Assignee: Molecular Templates, Inc.
    Inventors: Eric Poma, Erin Willert, Jack Higgins
  • Patent number: 11219678
    Abstract: A live attenuated Edwardsiella ictaluri bacterium lacking a viable gene encoding a functional evpB protein and a method of using the same to protect fish against infection from virulent Edwardsiella ictaluri. The methods and compositions for protecting fish against infection from virulent Edwardsiella ictaluri comprising administering to a fish a therapeutically effective amount of an attenuated Edwardsiella ictaluri bacterium lacking a viable gene encoding a functional protein selected from the group consisting of evpB, fur and hfq. The bacterium may include an insertion and/or deletion mutation in the gene. The fish include catfish, preferably catfish fingerling or a catfish fry. The composition may be delivered via immersion delivery, an injection delivery, an oral delivery, or combinations thereof.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: January 11, 2022
    Assignee: Mississippi State University
    Inventors: Attila Karsi, Mark Lawrence, Hossam Abdelhamed
  • Patent number: 11219679
    Abstract: The present disclosure is related to immunomodulatory bacterial minicells and methods of using the minicells.
    Type: Grant
    Filed: February 17, 2020
    Date of Patent: January 11, 2022
    Assignee: VAXIION THERAPEUTICS, LLC
    Inventor: Matthew J. Giacalone
  • Patent number: 11207395
    Abstract: The application is directed to in vitro-reared Plasmodium sporozoites of human host range wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same. Provided herein are in vitro-reared infectious Plasmodium sporozoites (SPZ) of human host range, particularly P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi, wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: December 28, 2021
    Assignee: Sanaria Inc.
    Inventors: Abraham G. Eappen, Stephen L. Hoffman
  • Patent number: 11209432
    Abstract: The disclosure provides methods, compositions, and kits for enhanced detection of microbes in samples and monitoring of antimicrobial activity in a subject.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: December 28, 2021
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Mark J. Cartwright, Nazita Gamini, Donald E. Ingber, Martin Rottman, Michael Super, Julie A. Tomolonis, Karen A. Sinclair
  • Patent number: 11204352
    Abstract: There is provided methods of determining tuberculosis (TB) infection status in an individual comprising: (i) providing a sample comprising T-cells; (ii) exposing the sample of (i) to one or more TB antigens; (iii) identifying T-cells in the sample that are CD4 positive and (a) secrete TNF-? without secreting IFN-?; or (b) secrete IFN-? without secreting TNF-?; (iv) identifying those cells of (iii) which are also CCR7 and, CD127 negative; and optionally (v) calculating the cells identified in (iv) as a percentage of those identified in (iii); wherein the identification of cells in (iv) and/or the percentage of T-cells calculated in (v) correlates to TB infection status of the individual, and wherein steps (iii) and (iv) can be carried out either sequentially or simultaneously. There are also provided compositions and kits for use in such methods.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: December 21, 2021
    Assignee: MJO Innovations Limited
    Inventors: Ajit Lalvani, Katrina Mary Pollock, Graham Taylor, Hilary Sian Whitworth
  • Patent number: 11197897
    Abstract: The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Clostridium scindens and/or the bacteria Blautia producta contribute substantially to resistance against vancomycin-resistant Enterococci infection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of Clostridium scindens.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: December 14, 2021
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Eric Pamer, Peter McKenney, Silvia Caballero
  • Patent number: 11193114
    Abstract: The invention describes new peptides containing epitopes recognized by CD4+ natural killer T (NKT) cells for increasing activity for use in infectious diseases, autoimmune diseases, immune reaction to administration of allofactors, allergic diseases, therapy of tumors, prevention of graft rejection and prevention of immunization against viral proteins used in gene therapy or gene vaccination.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: December 7, 2021
    Assignee: IMNATE SARL
    Inventor: Jean-Marie Saint-Remy
  • Patent number: 11173193
    Abstract: The invention relates to a method comprising the step of incubating chitosan in an aqueous solution of an organic carboxylic acid or a salt thereof, a modified chitosan obtainable by the method of the present invention, a hydro colloid, a compound of formula [X]n, a composition comprising the modified chitosan, the hydro colloid or compound according to the present invention, the modified chitosan, the hydro colloid, the compound or composition according to the present invention for use in human and/or veterinary medicine and the modified chitosan, the hydro colloid, the compound or composition according to the present invention for use in a method of treating and/or preventing mastitis, preferably latent mastitis and/or acute mastitis, endometritis, preferably chronic, acute and/or purulent-catarrhal endometritis, hoof- and claw diseases, lameness, lesions in the interdigital space, digital dermatitis, interdigital dermatitis, interdigital phlegmon, trichophytosis, microsporosis, mycosis of skin, allergies,
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: November 16, 2021
    Inventors: Igor Polyakov, Liudmila Ivanova
  • Patent number: 11168326
    Abstract: Provided are immunostimulatory bacteria and pharmaceutical compositions containing the bacteria. The immunostimulatory bacteria provided herein contain one or more modalities that enhance the anti-tumor activity of the immunostimulatory bacteria. Among the immunostimulatory bacteria provided are bacteria, such as Salmonella species, which are modified to be auxotrophic or are auxotrophic for adenosine and/or contain plasmids encoding RNAi, such as shRNA and microRNA, that mediate gene disruption and/or expression of immune checkpoints, such as TREX1, VISTA, PD-L1 and, genes that influence the immune system. The bacteria contain additional modifications to enhance their anti-tumor activity. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the pharmaceutical compositions.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: November 9, 2021
    Assignee: Actym Therapeutics, Inc.
    Inventors: Christopher D. Thanos, Laura Hix Glickman, Justin Skoble
  • Patent number: 11162944
    Abstract: A method of determining whether an individual is infected with a mycobacterial disease, the method comprising: (a) providing a system which comprises an antigen; (b) contacting the system with a sample obtained from the individual; and (c) detecting the presence or absence of binding of a biomarker in the sample with the antigen; wherein the antigen is an arabinose ester of a mycolic acid or an analogue thereof.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: November 2, 2021
    Assignee: DIAGNOSTIG LTD.
    Inventors: Mark Stephen Baird, Christopher David Gwenin, Juma'a Raheem Najeem Al-Dulayymi, Mohsin Omar Mohammed
  • Patent number: 11147843
    Abstract: The present invention provides a method of preventing or treating obesity by administering the probiotic bacterium of a novel Parabacteroides goldsteinii strain to the subject in need. The novel Parabacteroides goldsteinii strain is derived from the gastrointestinal tract of an individual and has better aero-tolerance and better acid-tolerance therefore it has better environmental tolerance to adapt to different living environments. The novel Parabacteroides goldsteinii strain not only can effectively prevent the weight gain of the individual, but also can effectively slow down the weight gain of the obese individual; therefore, the novel Parabacteroides goldsteinii strain of the present invention can be used for preparing a pharmaceutical composition for prevention and/or treating obesity.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: October 19, 2021
    Assignee: MULTISTARS BIOTECHNOLOGY COMPANY LIMITED
    Inventors: Po-I Wu, Chih-Jung Chang, Yu-Ling Tsai, Tzu-Lung Lin
  • Patent number: 11147865
    Abstract: The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B Streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: October 19, 2021
    Assignee: Pfizer Inc.
    Inventors: Annaliesa Sybil Anderson, Leena Shriram Bagle, Amardeep Singh Bhupender Bhalla, Miguel Angel Garcia, Lei Hu, Lakshmi Khandke, Avvari Krishna Prasad, Cindy Xudong Yang
  • Patent number: 11147860
    Abstract: The present invention relates to a liquid formulation containing botulinum toxin and stabilizing agent, and preparation method therefor. A liquid formulation containing botulinum toxin and stabilizing agent according to the present invention can be easily stored and distributed. It was proved a significant effect on the stabilization of botulinum toxin under suitable conditions according to the temperature and pH of the human body. Thus, it is expected that the pharmaceutical composition of the present invention will greatly contribute to the safe and convenient medical use of botulinum toxin.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: October 19, 2021
    Assignee: Hugel Inc.
    Inventors: Chee Gun Lee, Ji Hyun Oum
  • Patent number: 11141441
    Abstract: Bacterial hyperswarmers are disclosed for treatment, prevention and diagnosis of conditions such as intestinal inflammation.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: October 12, 2021
    Assignee: Albert Einstein College of Medicine
    Inventors: Sridhar Mani, Libusha Kelly, Hao Li
  • Patent number: 11135238
    Abstract: A method of treating a vulnerable atherosclerotic plaque can include identifying the vulnerable atherosclerotic plaque and administering a sulfated polysaccharide, or a pharmaceutically acceptable salt thereof, to a subject in an amount and at a frequency sufficient to stabilize and reverse a vulnerable atherosclerotic plaque.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: October 5, 2021
    Assignee: Calroy Health Sciences, LLC
    Inventors: Chen Chen, Miao Zhang, Edward Hoyt, Kevin Chen
  • Patent number: 11135279
    Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said immunogenic compositions.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: October 5, 2021
    Assignee: Pfizer Inc.
    Inventors: David Cooper, Kathrin Ute Jansen, Michael William Pride
  • Patent number: 11136358
    Abstract: The present invention relates to a plasmid-based CTX phage replication system and Vibrio cholerae strain that can be infected by CTX phage and can be used for cholera toxin production. More particularly, the present invention provides a Vibrio cholera variant strain, which expresses a toxT protein in which tyrosine at position 139 is substituted by phenylalanine through the point mutation of a toxT gene using a plasmid-based CTX phage replication system, and is used as a receptor strain which can improve CTX phage infection efficiency and allows a plurality of CTX prophages to simultaneously infect the strain and to be inserted into the chromosome thereof, which the consequent provision of the effect of increasing the production yield of a cholera toxin.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: October 5, 2021
    Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS
    Inventors: Dong Wook Kim, Eun Jin Kim, Hyun Jin Yu
  • Patent number: 11136396
    Abstract: The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography. The present invention also provides compositions, formulations, and unit dosage forms comprising the purified polypeptide or immunoconjugate.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: October 5, 2021
    Assignee: MedImmune Limited
    Inventors: Thomas Linke, William K. Wang, Ambarish Shah, Hasige Sathish, Alan Hunter, Christopher Thompson